Clinical trial
Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in…
NCT00427635 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00427635 |
|---|---|
| Title | Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients |
| Official title | A Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of Esomeprazole Once Daily for the Treatment of Gastroesophageal Reflux Disease (GERD) in Neonatal Patients, Including Premature and up to 1 Month Corrected Age |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | GERD |
| Intervention type | Drug |
| Interventions | Esomeprazole |
| Enrollment | 32 |
| Start date | Oct 1, 2006 |
| Completion | Apr 1, 2009 |
| First posted | Jan 29, 2007 |
| Last update posted | Dec 20, 2010 |
| Countries | Australia, Germany, United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: